Inside our digestive system lives a bustling community of trillions of bacteria that help break down the food we eat. These ...

Biologists have shown that the surfaces of plant leaves are coated with a diverse array of RNA molecules. The finding suggests that the RNA present on the leaf surface may play a role in shaping the ...

Challenge trials help researchers study immune responses. Skeptics still doubt the approach is worth the risks ...

A recent study reveals the pivotal role of tristetraprolin (TTP), an RNA-binding protein, in regulating inflammatory responses in basophils, immune cells central to allergic reactions. The research ...

Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based ...

At both Biotech Showcase and RESI JPM, BullFrog AI will highlight its proprietary BullFrog Data Networks ®, a data insights tool powered by the bfLEAP™ platform. BullFrog Data Networks ® evaluate high ...

PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma <a target=_blank href= ...

Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 ...

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose ...

Serna Bio, an AI drug discovery company pioneering RNA-targeting small molecules, today announced the members of its Scientific Advisory Board (SAB). Established in 2021, Serna Bio is a preclinical ...

Verismo Therapeutics, a clinical-stage CAR T company developing novel KIR-CAR platform technology, today announced that it has dosed the first patient in its CELESTIAL-301 Phase 1 clinical trial. The ...